Drug Profile
TBR 220
Alternative Names: TAK-220; TBR-220Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Takeda
- Developer Tobira Therapeutics
- Class Antiretrovirals; Piperidines; Small molecules
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections in Europe (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections in USA (PO)
- 01 Nov 2016 Tobira Therapeutics has been acquired by Allergan